Spravato is a brand name for the drug esketamine, which is specifically approved by the U.S. Food and Drug Administration (FDA) for the management of treatment-resistant depression in adults. Treatment-resistant depression refers to depression that has not adequately responded to other treatments, such as antidepressant medications.
Spravato is administered as a nasal spray typically in conjunction with an oral antidepressant medication, as part of a comprehensive treatment plan for depression. It is an NMDA receptor antagonist that acts on a pathway in the brain that affects glutamate, a neurotransmitter and has been found to significantly reduce depressive symptoms and episodes.
The nasal spray is self-administered under the supervision of your doctor or healthcare professional. The treatment is usually initiated with twice-weekly doses for the first month and then reduced to once-weekly or once every two weeks.